No Data
It has risen by the limit for two consecutive days! The loss-making pharmaceutical company "swallowed the elephant", and acquired a chip company valued at 10 billion under the control of the controlling shareholder.
A recent news of a pharmaceutical company's cross-border acquisition of a chip company has caused a sensation in the market. Originally, cross-border acquisitions are not something new, but the acquirer in this case is a loss-making pharmaceutical company with a market cap of only 2.16 billion before the suspension of trading; while the target acquisition is a profitable chip company with a valuation of 10 billion in the last round of equity transfer in 2021, which is a typical 'big fish eat small fish' scenario. Moreover, these two companies are both under the same ultimate controller, spanning two completely unrelated high-tech industries, making people marvel at the founder's incredibly broad ability border. Guolonghui learned that on the evening of September 10th, the listed company, hainan shuangcheng pharmaceuticals.
Hainan Shuangcheng Pharmaceuticals to Buy Chip Design Company; Shares Surge 10%
Hainan Shuangcheng Pharmaceuticals (002693.SZ): Intends to acquire 100% of the shares of Ora Pharmaceuticals. The resumption of trading will begin on September 11th.
Geelong on September 10th: Hainan Shuangcheng Pharmaceuticals (002693.SZ) announced that the listed company plans to issue shares and pay cash to Orat Investment, Win Aiming, and 25 other trading parties to purchase 100% of Orat's shares held by them and raise supporting funds from no more than 35 specific investors. As of the date of this summary, the audit and evaluation of the target assets have not been completed, and the specific transaction price of this transaction has not been determined. The target company of this transaction is mainly engaged in the research, design, and sales of analog chips and mixed-signal chips. The main products
Hainan Shuangcheng Pharmaceuticals Flags About 5.2 Million Yuan in Losses Due to Makar Typhoon
Hainan Shuangcheng Pharmaceuticals (002693.SZ): Preliminary estimation of losses due to typhoon disaster is about 5.2 million yuan.
On September 6th, 2024, Hainan suffered from Super Typhoon "Moji" No.11 this year. The company's factory is located at No. 16, Xingguo Road, Xiuying District, Haikou City, Hainan Province. It was affected by the combination of typhoons and heavy rains, causing damage to some equipment, facilities, and systems in the factory area. As of now, the company's losses in this typhoon disaster are mainly concentrated in the damaged equipment and system engineering, with an estimated loss of about 5.2 million yuan, but no casualties occurred. After the typhoon disaster, the company actively invested in resuming work and production. As of the date of this announcement,
Shuangcheng Pharmaceutical: Semi-Annual Report 2024
Here's Why Hainan Shuangcheng Pharmaceuticals (SZSE:002693) Can Afford Some DebtNo Data
No Data
